These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 34452716)
21. 'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L. Åström M; Conte H; Berg J; Burström K Qual Life Res; 2022 Jul; 31(7):2133-2142. PubMed ID: 35201557 [TBL] [Abstract][Full Text] [Related]
22. In search of a 'pan-European value set'; application for EQ-5D-3L. Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the measurement properties and consistency between the EQ-5D-3L and EQ-5D-Y-3L in adolescents aged 15-17 in China. Wang J; Hong T; Fang H; Luo C; He X; Xie S Health Qual Life Outcomes; 2024 Jul; 22(1):59. PubMed ID: 39075537 [TBL] [Abstract][Full Text] [Related]
24. Population-level norm values by EQ-5D-3L in Hungary - a comparison of survey results from 2022 with those from 2000. Inotai A; Nagy D; Kaló Z; Vokó Z Qual Life Res; 2024 Sep; 33(9):2417-2428. PubMed ID: 38839684 [TBL] [Abstract][Full Text] [Related]
25. Population health status based on the EQ-5D-Y-3L among adolescents in Sweden: Results by sociodemographic factors and self-reported comorbidity. Åström M; Persson C; Lindén-Boström M; Rolfson O; Burström K Qual Life Res; 2018 Nov; 27(11):2859-2871. PubMed ID: 30196340 [TBL] [Abstract][Full Text] [Related]
26. To What Extent Do Patient Preferences Differ From General Population Preferences? Ludwig K; Ramos-Goñi JM; Oppe M; Kreimeier S; Greiner W Value Health; 2021 Sep; 24(9):1343-1349. PubMed ID: 34452715 [TBL] [Abstract][Full Text] [Related]
27. Estimating an EQ-5D-Y-3L Value Set for China. Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878 [TBL] [Abstract][Full Text] [Related]
28. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study. Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896 [TBL] [Abstract][Full Text] [Related]
29. Valuation of the EQ-5D-3L in Russia. Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323 [TBL] [Abstract][Full Text] [Related]
30. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886 [TBL] [Abstract][Full Text] [Related]
31. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values. Selivanova A; Buskens E; Krabbe PFM Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559 [TBL] [Abstract][Full Text] [Related]
32. An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L. Khanna D; Khadka J; Mpundu-Kaambwa C; Chen G; Dalziel K; Devlin N; Ratcliffe J; Pharmacoeconomics; 2024 Jun; 42(Suppl 1):113-128. PubMed ID: 38280125 [TBL] [Abstract][Full Text] [Related]
33. Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. Zrubka Z; Golicki D; Prevolnik-Rupel V; Baji P; Rencz F; Brodszky V; Gulácsi L; Péntek M Eur J Health Econ; 2019 Jun; 20(Suppl 1):141-154. PubMed ID: 31102159 [TBL] [Abstract][Full Text] [Related]
34. An experience- and preference-based EQ-5D-3L value set derived using 18 months of longitudinal data in patients who sustained a fracture: results from the ICUROS. Svedbom A; Borgstöm F; Hernlund E; Alekna V; Bianchi ML; Clark P; Diaz-Curiel M; Dimai HP; Jürisson M; Lesnyak O; McCloskey E; Sanders KM; Silverman S; Tamulaitiene M; Thomas T; Tosteson ANA; Jönsson B; Kanis JA Qual Life Res; 2023 Apr; 32(4):1199-1208. PubMed ID: 36495384 [TBL] [Abstract][Full Text] [Related]
35. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730 [TBL] [Abstract][Full Text] [Related]
36. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242 [TBL] [Abstract][Full Text] [Related]
37. Feasibility of Proxy-Reported EQ-5D-3L-Y and Its Agreement in Self-reported EQ-5D-3L-Y for Patients With Adolescent Idiopathic Scoliosis. Lin J; Wong CKH; Cheung PWH; Luo N; Cheung JPY Spine (Phila Pa 1976); 2020 Jul; 45(13):E799-E807. PubMed ID: 32539293 [TBL] [Abstract][Full Text] [Related]
38. A Value Set for the EQ-5D-Y-3L in the Netherlands. Roudijk B; Sajjad A; Essers B; Lipman S; Stalmeier P; Finch AP Pharmacoeconomics; 2022 Dec; 40(Suppl 2):193-203. PubMed ID: 36216977 [TBL] [Abstract][Full Text] [Related]
39. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC; Value Health; 2009; 12(5):750-8. PubMed ID: 19490564 [TBL] [Abstract][Full Text] [Related]
40. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Feng Y; Herdman M; van Nooten F; Cleeland C; Parkin D; Ikeda S; Igarashi A; Devlin NJ Qual Life Res; 2017 Aug; 26(8):2067-2078. PubMed ID: 28343350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]